Lv2
120 积分 2022-09-13 加入
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
21天前
已完结
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
21天前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
22天前
已完结
A compendium of promoter-centered long-range chromatin interactions in the human genome
1个月前
已完结
Long-range enhancer–promoter contacts in gene expression control
1个月前
已完结
Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis
2个月前
已完结
HIV immune evasin Nef enhances allogeneic CAR T cell potency
3个月前
已完结
Highly enriched BEND3 prevents the premature activation of bivalent genes during differentiation
4个月前
已完结
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
4个月前
已完结
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
5个月前
已完结
Elucidation and de novo Reconstitution of Glyceollin Biosynthesis
20天前
已驳回
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
20天前
已采纳
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
5个月前
已采纳
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
5个月前
已采纳
皖公网安备34019202002308
